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Abstract
Background: Death certificates can be used to assess disease prevalence and incidence; however, rheumatoid arthritis
(RA) often remains unreported in death certificates. We sought to determine to what extent RA is underreported and
what demographic and clinical characteristics could predict mention of RA in the death certificate.
Methods: We recruited 1328 patients with RA from private, public and military rheumatology practices and followed
them prospectively for yearly evaluations. A rheumatologist assessed clinical characteristics of RA and comorbidities at
each evaluation. Deaths were identified through family members, other physicians, obituaries and public death databases.
All were confirmed with state-issued death certificates. Patients with and without RA in death certificate were compared
using bivariate and multivariate analyses.
Results: By December 2013, 326 deaths had occurred. We received and reviewed death certificates for all confirmed
deaths, of which 58 (17.7 %) mentioned RA on the death certificate. Bivariate analysis revealed that younger age, a greater
number of deformities, higher Sharp score and lower socioeconomic status were each associated with recording RA.
Multivariable analyses revealed that comorbidity [OR (95 % CI) = 0.84 (0.73, 0.97); P = 0.022] was inversely associated with
listing RA on the death certificate, while the number of deformities [OR (95 % CI) = 1.04 (1.00, 1.07);
P = 0.033] and a certified physician’s signature on the death certificate [OR (95 % CI) = 4.79 (1.35, 16.9); P = 0.015] increased
likelihood of reporting RA.
Conclusion: In this cohort, RA was not listed in over 80 % of death certificates. Younger patients with fewer
comorbidities and more joint deformities were more likely to have RA reported.
Discussion: RA is often not included in death certificates. The findings of this study suggest that older patients may have
a greater number of comorbidities, thus decreasing the likelihood that RA be included when completing the death
certificate.
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Background
Rheumatoid arthritis (RA) is a chronic disease character-
ized by joint inflammation that affects approximately
1 % of Americans [1]. Although ultimate causes of death
in RA patients are similar to the general population [2],
mortality rates in RA patients are 1.5 – 1.6 times higher
[2, 3]. However, despite such a high mortality, previous
studies have indicated that RA may be underreported in
death certificates with anywhere between 50 and 89 %
lacking mention of the disease [2, 4–6]. The tendency to
under-report RA on death certificates has persisted since
it was first reported half a century ago [2].
Death certificates are important tools used in epidemio-
logical research. Yet physicians completing them may be un-
aware of underlying conditions. Although rheumatic diseases
such as RA are not often considered immediate causes of
death, they may predispose patients to comorbidity that may
directly cause mortality, such as cardiovascular (CV) disease
[7, 8]. Moreover, some commonly used treatments may pre-
dispose RA patients to burdensome side effects [9, 10] and
increased mortality [11]. Without identifying RA as an
underlying condition, epidemiological studies that rely on
information from death certificates may not fully ascertain
the morbidity and mortality of the disease.
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In this study, we examine frequency of reporting RA




From 1996 to 2009, we recruited consecutive patients
who met the 1987 criteria for RA [12] from private, pub-
lic and military rheumatology practices in San Antonio,
Texas. We have described part of this cohort in previous
publications [13–15]. All patients granted informed con-
sent before participating in a comprehensive baseline
evaluation of their clinical and psychosocial characteris-
tics conducted by a physician and trained research assis-
tants. Afterwards, we invited them for annual follow-up
evaluations through the censor date of December 31,
2013. Throughout 2014, we underwent further efforts to
ascertain vital status of patients by contacting patients
and families directly. We learned about deaths from
public databases, physicians, relatives, neighbors and ob-
ituaries. All deaths were confirmed by death certificate.
This study received approval from the institutional
review board at the University of Texas Health Science
Center at San Antonio.
Demographics
A trained interviewer asked patients for their date and
place of birth, sex and race/ethnicity. For the latter, the
interviewer asked patients to self-identify as “white,”
“black,” “Asian,” “Hispanic,” or “other.”
Socioeconomic status
We classified socioeconomic status (SES) according to
Nam and Powers, using years of formal education,
inflation-adjusted monthly household income, and current
or past occupation at baseline to calculate an SES score
on an ascending scale between 0 and 100 [16]. Health in-
surance information was obtained at each evaluation.
Analyses included insurance information from the most
recent visit prior to death.
Clinical features
Body Mass Index (BMI)
Obesity was measured at each encounter by assessing
BMI, which is calculated as weight in kilograms divided
by the square of the height in meters. In this study, we
used the BMI from the most recent visit.
Joint findings
A physician examined 48 joints for tenderness or pain
on motion, swelling or deformity, and for the presence
of extra-articular subcutaneous nodules [17]. Joint exam
Spearman-Brown reliability coefficients are 0.94 for ten-
der/pain on motion, 0.90 for swelling and 0.98 for
deformity [18]. In these analyses, we used the 28 joints
included in the DAS28ESR from the most recent visit.
Hand radiographs
We quantified joint damage on a plain X-ray view of
both hands and wrists according to Sharp and colleagues
[19]. In this study, all X-ray radiographs were scored by
one rater (JFR). Analyses included radiographs from the
most recent visit prior to death.
Rheumatoid nodules
Absence or presence of rheumatoid nodules was deter-
mined by a rheumatologist at each patient evaluation. In
this study, nodules were considered present if they were
found in the most recent visit prior to death.
Steinbrocker functional class
The Steinbrocker functional classification [20] was assigned
by the physician or a research nurse who was trained in
physical function assessment. The Steinbrocker func-
tional classification is used to rate the extent of phys-
ical disability on a 4-level scale. Spearman-Brown
reliability of the Steinbrocker classification in our
study was 0.84.
Comorbidity
The comorbidity scale that we used was the Charlson
Comorbidity Index [21]. This index records the presence
or absence of 18 health problems, each one weighted for
severity according to predefined values. The final score
is provided by the sum of the weights of each patient’s
health problems. The examining physician used a vali-
dated self-report questionnaire to interview the patients
about the presence or absence of the predefined health
problems [22]. The physician then reviewed available
medical records to verify the problems reported by the
patient. If discrepancies between the medical record and
the self-reported responses arose, the case was discussed
among 3 or 4 physicians in order to decide on the final
score. Interrater reliability was 0.94 [23].
Information on the death certificate
To confirm deaths, state-issued death certificates were
obtained from the state in which the patient died. Imme-
diate cause of death listed and any underlying conditions
were coded using the International Classification of Dis-
eases, Version 9 (ICD-9) by an experienced nosologist.
We recorded whether a certified physician, medical
examiner or a justice of the peace signed the death cer-
tificate. Place of death was ascertained by the death cer-
tificate and was categorized as either “home,” “hospital,”
“nursing home,” or “other.” We further noted if an aut-
opsy was performed and if those results were available at
the time the death certificate was written.
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Statistical analysis
Bivariate analyses were conducted to compare patients
with and without RA recorded on the death certificate.
We assessed differences in demographics, socioeco-
nomic status, and clinical characteristics between the
two groups using t-tests. We further conducted a series
of multivariable logistic regressions to identify which fac-
tors are independently associated with recording RA. In
the final multivariable model, we included variables that
were found to be significant in bivariate analyses as well
as potential confounders (sex, ethnicity, socioeconomic
status, etc.). Moreover, because the Charlson Comorbid-
ity score is not linearly distributed, we divided the vari-
able into tertiles for the final multivariable model. When
examining overall mortality in RA, we calculated death
rate for all-cause and CV mortality.
All analyses were conducted using a desktop personal
computer with the Stata statistical software package, ver-
sion 9.0 (College Station, TX).
Results
There were a total of 1328 participants recruited be-
tween 1996 and 2009. By December 2013, 326 deaths
had occurred during 8966 person-years of observation,
for a mortality rate of 3.6 per 100 person-years [95 %
confidence interval (CI) (3.3, 4.0)]. Average age (range)
at death was 71.8 years (46.1 - 92.8 years). Moreover,
most of the patients (55.5 %) died in a hospital, though
there were no significant differences in immediate cause
of death by the place of death. Of the 326 death certifi-
cates we received, 58 (17.7 %) mentioned RA on the
death certificate. Of the 58 certificates, 2 recorded RA as
the immediate cause of death, 22 recorded it as a cause
leading up to death, and 34 recorded it as an underlying
condition not directly contributing to the cause of death.
Because we followed patients for numerous visits over
several years, we used the most recent information prior
to death. Average time between death and the most re-
cent evaluation was 2.19 years (0.01 – 10.1 years). By
comparing patients with and without RA listed on the
death certificate, we found that patients who were younger
at the time of death (P-value = 0.05), had lower socioeco-
nomic status (P = 0.011), a greater number of deformities
(P = 0.008), and higher Sharp score (P = 0.003) were more
likely to have RA recorded on the death certificate
(Table 1). There were no significant differences in sex,
ethnicity or presence of health insurance between the two
groups. Other factors such as immediate cause of death,
place of death, presence of rheumatoid nodules, and per-
forming an autopsy were also not associated with record-
ing RA in bivariate analyses.
We sought to determine what factors were independ-
ently associated with recording RA through multivari-
able analyses. Because we found that having a greater
number of deformities [OR (95 % CI) = 1.04 per deform-
ity (1.00, 1.07); P = 0.033] and a fewer number of comor-
bidities [OR (95 % CI) = 0.84 (0.73, 0.97); P = 0.022]
increased likelihood of reporting RA after adjusting for
confounders such as age, sex, ethnicity and socioeco-
nomic status, in our final model, we divided both of
these variables into tertiles (Table 2). At the time of
death, 112 patients had between 0 and 9 deformities,
108 patients had between 10 and 21, and 106 patients
had between 22 and 28. Patients in the tertile with the
greatest number of deformities were 2.48 times more
likely to have RA recorded than those in the tertile with
the fewest deformities (Table 2). There were 127 patients
with a Charlson comorbidity score between 1 and 3, 101
between 4 and 5, and 98 between 6 and 14. In this final
model, we found that age [OR (95 % CI) = 0.97 (0.94,
1.00); P = 0.06] no longer remained significantly inversely
associated with having RA recorded. However, compared
to patients with the least comorbidity, those with the
most were significantly less likely to have RA mentioned
on the death certificate [OR (95 % CI) = 0.32 (0.14, 0.75);
P = 0.008]. Moreover, in this model, having a certified
physician sign the certificate [OR (95 % CI) = 4.97 (1.39,
17.7); P = 0.013] increased the likelihood that RA would
be reported (Table 2).
The most common immediate cause of death was CV-
related, with 111 (34.0 %) deaths resulting from disease
of the circulatory system (ICD-9 codes between 390 and
459) (Table 1). However, we found an additional 61
death certificates listed CV disease as an underlying con-
dition, summing to a total of 171 (52.6 %) of deaths
resulting from CV causes (Table 3). Interestingly, al-
though only 58 death certificates listed RA, an additional
10 death certificates mentioned other musculoskeletal
diseases (ICD-9 codes between 710 and 739) such as sys-
temic lupus erythematosus, CREST (calcinosis, Raynaud
phenomenon, esophageal dysmotility, sclerodactyly, and
telangiectasia) syndrome or mixed connective tissue dis-
ease without mentioning RA (Table 3), likely represent-
ing overlap conditions with RA. None of these 10
patients received autopsies. We reviewed our comorbid-
ity data and confirmed that these patients had overlap-
ping musculoskeletal conditions.
Discussion
Previous studies have suggested that death certificates in
RA may be unreliable [2, 4–6]. This was first noted in
1967, by Atwater and Jacox, who found that less than
50 % of death certificates for RA patients mentioned the
disease [5]. Since then, several studies have found similar
results [2, 4, 6]. In 2008, Sokka et al. reviewed over 50
cohorts between the years 1953–2008 and found that little
has changed in the past 30 years, with only an average of
9.4 % death certificates in RA mentioning musculoskeletal
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disease [2]. In our study, we evaluated 326 death certifi-
cates and not only confirmed that RA remains widely
under-reported, but also assessed what predictive factors
may contribute to successfully indicating the presence of
RA in vital statistics. One unique aspect of our study is
the availability of detailed clinical and laboratory ante-
mortem data. This information allowed us to examine fac-
tors associated with reporting of RA.
We describe demographic and clinical characteristics
of 326 RA patients and their corresponding death certifi-
cates. On average, patients with RA recorded in the
death certificate were younger at death, had a greater
number of joint deformities, and a higher Sharp score
(Table 1). These results are not surprising because RA
becomes more obvious to the physician or medical exam-
iner when patients have a greater number of deformities.
Patients with fewer deformities may not be as readily iden-
tified as arthritis patients.
Moreover, patients who were younger at death may
have less comorbidity to report, thus bringing chronic
rheumatic diseases to the forefront of relevant diag-
noses to mention in the death certificate. A study
examining the reporting of systemic lupus erythema-
tosus (SLE) mortality noted that 40 % of death certifi-
cates lacked mention of SLE [24]. These authors
found that older patients and those without health in-
surance were less likely to have SLE recorded. Al-
though in our RA cohort there was no indication that
presence of health insurance affected the complete-
ness of the death certificate in regards to RA, we did
find similar results regarding age (Table 1). However,
our final analytical model suggests lower comorbidity
in RA is the underlying reason for this association, as
a lower comorbidity score remains independently as-
sociated with recording RA, not older age (Table 2).
Older patients may have a greater number of comor-
bidities, thus increasing the likelihood that RA could
be overlooked when completing the death certificate.
As the average age of RA onset increases [1], this
may bias future studies on mortality in RA towards youn-
ger patients with more severe disease and less comorbidity.
Furthermore, aside from greater joint deformities
and less comorbidity, the only other variable analyzed
that independently correlated with recording RA on
Table 1 Bivariate analyses of 326 RA patients with and without
RA on the death certificate
RA recorded
Demographics Yes (n = 58) No (n = 268) P-value
Age in years at time of death,
mean (SD)
69.3 (9.8) 72.3 (10.1) 0.05
Women, n(%) 36 (62.1) 161 (60.3) .8
Ethnicity, n (%)
White 23 (39.7) 127 (47.6) .3
Black 2 (3.4) 16 (6.0) -
Asian 2 (3.4) 1 (0.4) -
Hispanic 31 (53.4) 123 (45.9) 0.3
Other 0 1 (0.4) -
Socioeconomic status
Nam & Powers Score,
mean (SD)
41.0 (2.8) 48.4 (1.20) 0.011
Had insurance at most recent
visit, n(%)
54 (93.1) 259 (96.6) .2
Clinical characteristics
Disease duration in years,
mean (SD)
22.7 (13.0) 21.6 (12.0) 0.5
Presence of rheumatoid
nodules, n(%)
37 (63.7) 148 (55.2) 0.2
Deformities of 28 joints,
mean (SD)
17.6 (9.3) 14.0 (9.2) 0.007
Sharp Scorea, mean (SD) 196.2 (133) 135.6 (109) 0.003
Steinbrocker functional class
Class II, n(%) 19 (32.8) 121 (45.1) 0.08
Class III, n(%) 24 (41.4) 95 (35.6) 0.4
Class IV, n(%) 14 (24.1) 40 (15.0) 0.08
Charlson Comorbidity Index,
mean (SD)
4.09 (2.3) 4.57 (2.4) 0.2
BMI, mean (SD) 26.0 (6.9) 27.5 (6.4) 0.1
Death certificates
Autopsy Performed, n (%) 3 (5.1) 16 (5.9) 0.8
Who signed Death Certificate, n(%)
Certified Physician 55 (94.8) 228 (85.1) 0.046
Medical Examiner 3 (5.2) 36 (9.8) 0.08
Justice of the Peace 0 (0) 4 (1.5) 0.4
Place of Death, n (%)
Home 17 (29.3) 70 (26.1) 0.6
Hospital 33 (56.9) 148 (55.4) 0.8
Nursing Home 5 (8.6) 30 (11.2) 0.6
Other 3 (5.2) 20 (7.5) 0.5
Primary Cause of Death, n(%)
Cardiovascular (n = 111) 15 (25.9) 96 (35.8) 0.1
Respiratory (n = 68) 16 (27.6) 52 (19.5) 0.2
Table 1 Bivariate analyses of 326 RA patients with and without
RA on the death certificate (Continued)
Neoplasms (n = 51) 12 (20.7) 39 (14.6) 0.2
Infection (n = 27) 5 (8.6) 22 (8.2) 0.9
Rheumatoid Arthritis
(n = 2)
2 (3.4) 0 -
Other (n = 67) 8 (13.8) 59 (22.1) 0.2
aHand radiographs were not available for 76 of the 326 deceased RA patients.
Of these, 20 had RA listed on the death certificate, while 56 did not
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the death certificate was having a certified physician
signed the death certificate (Table 2). Of the 58 death
certificates that reported RA, a certified physician
signed 55. At first, this result was surprising; medical
examiners require a medical degree and therefore are
well versed in medicine as well as forensic science.
However, when a certified physician signs, they are
more likely to know the patient history compared to
a medical examiner or justice of the peace [25]. Therefore,
regardless of the number of discernible joint deformities,
these physicians are familiar with a patient’s case and can
consequently report RA accordingly. Nevertheless, while
having a certified physician sign increased likelihood of
RA being reported in our cohort, still only 55 (19.5 %) of
the 282 death certificates signed by a certified physician
listed RA at all.
Although death certificates were not originally
intended for epidemiological research, they have be-
come useful tools when examining mortality in popu-
lation and cohort studies. Therefore, incomplete or
inaccurate records have many implications for re-
search that rely on these records. Given that diseases
of the musculoskeletal system are not often consid-
ered immediate causes of death, completeness of re-
cording underlying conditions in the death certificate
becomes crucial when analyzing mortality of these
diseases. Although many patients may not die dir-
ectly from RA and therefore do not have it included
as an immediate cause of death or as a cause leading
up to death, there is a separate section for under-
lying chronic conditions where RA may still be
mentioned.
A number of studies have suggested that the higher
mortality in RA compared to the general population
has not decreased over the past several decades [3, 26],
with CV disease being the most common cause of death
[2]. Our results further suggest CV disease remains the
most common cause of death with 52.6 % of death certifi-
cates listing a disease of the circulatory system (ICD-9
codes 390 – 459) as the immediate or underlying cause of
death (Table 3). Nevertheless, it has been noted in the
general population that CV disease may be over-reported
in death certificates [27].
Interestingly, although only 58 death certificates
listed RA in the total cohort, an additional 10 listed
other musculoskeletal conditions. Although none of
these 10 patients received autopsies, certified physi-
cians signed all of these death certificates. However,
when reviewing comorbidity in each of these cases,
all 10 patients had overlap with another musculoskel-
etal disease, such as lupus, mixed connective tissue
disease or Sjögren’s syndrome. The overlap in these
diseases is thus an additional barrier to completing the
death certificate with accurate representation of RA.
Our study on the reporting of death certificates has
several strengths and weaknesses. We have mentioned
the rich variety of ante-mortem data that allowed us to
examine the patient characteristics associated with RA
reporting. Moreover, we recruited participants from sev-
eral public, private and military health clinics throughout
San Antonio, resulting in a diverse cohort from a variety
of backgrounds. Because our patients were all recruited
from San Antonio, Texas, the geographic coverage may
limit our generalizability. However, underreporting of
rheumatic diseases in death certificates has been noted
from patients recruited in other states [5, 24], as well as
other countries [4, 6].
Table 3 Immediate cause of death and underlying conditions
found in 326 RA death certificates by ICD-9 code
Condition (ICD-9 code range) Total death certificates
listing condition (%)a
Infectious & Parasitic Diseases
(001 – 139)
55 (16.9 %)
Neoplasms (140 – 239) 69 (21.2 %)
Diseases of the Circulatory System
(390 – 459)
172 (52.7 %)
Diseases of the Respiratory System
(460 – 519)
123 (37.8 %)
Diseases of the Musculoskeletal Systemb
(710 – 739)
68 (20.9 %)
aPercentages add up to more than 100 % as many patients had more than
one underlying condition across several ICD-9 code categories
bTen patients have ICD-9 codes for Diseases of the Musculoskeletal System
listed on the death certificate, but do not list RA
Table 2 Multivariable analyses of factors associated with
recording RA in death certificates (n = 326)
Independent variable Odds ratio (OR) 95 % CI P-value
Age 0.97 0.94, 1.00 0.06
Sex (Female==1) 0.78 0.41, 1.51 0.5
Non-Hispanic White ethnicity 1.1 0.56, 2.19 0.8
Health Insurance (yes==1, no==0) 0.57 0.15, 2.10 0.4
Nam & Powers Score 0.98 0.97, 1.00 0.1
Number of Deformities (0–9) 1.0 REFERENT –
Number of Deformities (10–21) 1.01 0.45, 2.33 0.9
Number of Deformities (22–28) 2.48 1.1, 5.6 0.03
Steinbrocker Functional Class 1.0 REFERENT –
Class II 1.53 0.18, 13.4 0.7
Class III 2.13 0.23, 19.4 0.5
Class IV 1.90 0.19, 18.7 0.6
Charlson Comorbidity (range 1–3) 1.0 REFERENT –
Charlson Comorbidity (range 4–5) 0.82 0.40, 1.68 0.6
Charlson Comorbidity (range 6–14) 0.32 0.14, 0.75 0.008
Signed by Certified Physician 4.97 1.39, 17.7 0.013
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Conclusions
The present study suggests that RA is often underre-
ported in death certificates, with less than 20 % of death
certificates from our cohort accurately mentioning the
disease. Studies of mortality in RA that rely on death
certificates may be biased towards younger patients with
more severe RA and less comorbidity. More research is
needed to determine what other factors may explain this
underrepresentation, as well as what may prevent this
discrepancy in the future.
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